# NIH grant: Immobilized Cofactor Regeneration Systems to Accelerate Enzymatic API Manufacturing (1R43TR006332-01) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/5269bf6f9acdb9d1

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-08-15 00:00 ingested 2026-08-17 06:48

[original source ↗](https://reporter.nih.gov/project-details/1R43TR006332-01)

## retained text



```
NIH grant 1R43TR006332-01: Immobilized Cofactor Regeneration Systems to Accelerate Enzymatic API Manufacturing
Institute: {'code': 'TR', 'abbreviation': 'NCATS', 'name': 'National Center for Advancing Translational Sciences', 'admin_org_id': '12500062', 'admin_funding_url': ''}. PI: James  Weltz. Award: $306871.
Start: 2026-08-15T00:00:00.
Title: Immobilized Cofactor Regeneration Systems to Accelerate Enzymatic API Manufacturing
Cascade Biocatalysts Inc.
Project Summary/Abstract
Enzymes – nature’s catalysts – are recognized as a powerful approach for pharmaceutical manufacturing.
Enzymatic processes can replace traditional chemical routes with methods that are more selective, operate
under mild conditions, and open access to novel drug chemistries previously inaccessible to manufacturers.
These advantages are especially important for strengthening U.S. capacity to produce medicines, reducing
reliance on global supply chains, and supporting less resource intensive domestic manufacturing.
Despite these benefits, widespread adoption of biocatalysis is limited by the poor stability of enzymes under
process conditions and the complexity of recycling required cofactors. Since nearly half of all enzymes require a
cofactor, this challenge restricts the use of a large portion of nature’s catalytic toolkit. To address this, we will
expand an enzyme immobilization platform by incorporating cofactor regeneration systems directly into
immobilized resins, enabling broader application of redox enzymes and transferases in pharmaceutical
synthesis.
Our research strategy includes the design and synthesis of immobilized cofactor-regeneration resins, followed
by rigorous evaluation of stability, activity, and reusability in representative pharmaceutical reactions. Success
will establish a broadly applicable platform that reduces barriers to implementing biocatalysis earlier in drug
process development. The long-term objective is to accelerate the adoption of enzyme-based manufacturing
routes, increasing efficiency and resilience of domestic pharmaceutical production while opening new
opportunities for innovative medicines.
```



document fetched 2026-08-23 06:34